Best Practices for Post-Marketing Surveillance of Adverse Events within the U.S.
Medical and scientific progress has been enormous in the past decades. However, this has also raised several safety issues leading to increased vigilance on bio-pharma companies by the U.S. Food and Drug Administration Authority. Under such circumstances, it is imperative for the bio-pharmaceutical industry to maintain a dynamic post-marketing surveillance system to ensure regulatory compliance.
This benchmarking study examines the best practices for post-marketing surveillance within the United States, as well as the processes for assessing reports of adverse events, follow-up activities and compliance training.
Executives and managers in Drug Safety can use this research to compare their group's staffing, makeup, AE evaluation process, reporting sources, follow-up activities and training with those of leading organizations.
Business Operations > Health and Safety d
Industries Profiled:
Pharmaceutical; Health Care; Biotech; Service
Companies Profiled:
Novartis; Boehringer Ingelheim; Wyeth Pharmaceuticals; Novo Nordisk; Apotex; Stiefel; EMD Serono; Sepracor; Amgen; Biogen Idec; Vertex Pharmaceuticals; Eisai; Takeda Pharmaceuticals; Bracy Analytics Inc; ArthroWave
Study Snapshot
This benchmarking report examines the best practices for post-marketing surveillance within the United States, as well as the processes for assessing reports of adverse events, follow-up activities and compliance training. Executives and managers in Drug Safety can use this research to compare their group's staffing, makeup, AE evaluation process, reporting sources, follow-up activities and training with those of leading organizations. Representatives from 15 leading companies have shared their practices, views and information, to facilitate post-market surveillance system. Following are the key topics covered in this report:
- Staffing and Workflow
- Drug Safety Processes and Reporting Sources
- Approach to AE Reports from Non-Traditional Sources
- Approach to AE Reports on Another Manufacturer’s Product
- Drug Safety Compliance Training
- Marketing Program Involvement
- Drug Safety Challenges
Back to Top
Key Findings
Staff Resources and Makeup: 80 percent of companies use physicians to review adverse event (AE) reports, more than 50 percent of benchmark partners also use pharmacists and nurses as reviewers.
Post-Marketing Surveillance Process: Some drug safety activities appear common in the industry, such as outsourcing low-level work and forwarding all AE reports of other manufacturers. Nearly 60 percent of the benchmark class outsource low-level work such as data entry within their drug safety groups.
Post-Marketing Adverse Events Reporting: Most of the companies said they report from a list of varied sources, 50 percent said they do not report from non-traditional sources such as blogs and interactive Web events.
Back to Top
Related Research:
|